Routine annual meeting filing with no immediate trading implications. Monitor future 10-Q filings for potential dilution from equity grants under the new plan.
PTGX drugs
PTGX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 22 $115.03entry
- T+1 · 5mo ago +3.42%α +4.87% · $118.96
- T+5 · 5mo ago +5.96%α +8.02% · $121.88
- T+20 · 4mo ago +22.50%α +22.65% · $140.91
- T+60 · 2mo ago +24.66%α +22.92% · $143.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protagonist Therapeutics held its 2026 Annual Meeting on June 17, 2026, where stockholders approved the new 2026 Equity Incentive Plan, replacing the 2016 plan and adding 650,000 new shares plus the prior plan's available reserve and returning shares. The election of two Class I directors and the ratification of Ernst & Young as auditor were also approved. This is a routine governance filing that does not change the company's operational outlook or financial position.
Key Facts
- Stockholders approved the 2026 Equity Incentive Plan, adding 650,000 new shares plus the prior plan's available reserve and returning shares to the share reserve.
- Two Class I directors were elected: Dinesh V. Patel, Ph.D. (48,714,702 for) and Lewis T. Rusty Williams, M.D., Ph.D. (45,371,193 for).
- Stockholder approval was received for executive compensation (say-on-pay) and the appointment of Ernst & Young as independent registered public accounting firm.
- The 2026 Plan replaces the 2016 Equity Incentive Plan and allows for grants of options, SARs, restricted stock, RSUs, and other stock-based awards.
- As of the record date (April 22, 2026), there were 64,305,185 shares of common stock outstanding and entitled to vote.
Financial Impact
Equity incentive plan refresh; 650,000 new shares authorized; no material near-term financial impact.
Risk Factors
- Potential dilution from future equity grants under the new plan.
- No change to operational or financial guidance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-075777 |
| Document: tm2618251d1_8k.htm | 0001104659-26-075777 |
| Document: 0001104659-26-075777-index-headers.html | 0001104659-26-075777 |
| Document: 0001104659-26-075777-index.html | 0001104659-26-075777 |
| Document: 0001104659-26-075777.txt | 0001104659-26-075777 |
Track record
11 reports on PTGX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
- Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
- Jun 18, 202621w ago 8-K Neutral 3/10 Viewing Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
- May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers